Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmaceopidemiol Drug Safety 2010;19: epub ahead of print May 19.

Schneeweiss S, Patrick AR, Solomon DH, Metha J, Dormuth C, Miller M, Lee J, Wang PS. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: A propensity score-adjusted analysis of 9 years of data. Arch Gen Psychiatry 2010;67:497-506.

Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, Schneeweiss S. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010;303:1401-9.

Schneeweiss S, Patrick AR, Solomon DH, Metha J, Dormuth C, Miller M, Lee J, Wang PS. The comparative safety of antidepressant agents in children regarding suicidal acts. Pediatrics 2010;125: 876–88.

Rassen JA, Choudhry N, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention. Circulation 2009;120:2322-9.

Schneeweiss S, Avorn J.  Antipsychotic agents and sudden cardiac death – how to manage the risk. N Engl J Med 2009;360:294-6.

Schneeweiss S, Seeger CD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008;358:771-83.

Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int J Biostat 2007;3:14-.

Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, Maclure M, Rothman K, Glynn RJ. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Medical Care 2007;45:S131-42.

Brookhart MA, Rassen JA, Wang PS, Dormuth C, Mogun H, Schneeweiss S. Evaluating the validity of an instrumental variable study of neuroleptics: Can between-physician differences in prescribing patterns be used to estimate treatment effects? Medical Care 2007;45:S116-22.

Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharm Ther 2007;82:143-56.

Schneeweiss S, Patrick A, Maclure M, Dormuth C, Glynn RJ. Adherence to statin therapy under drug cost-sharing in patients with and without acute MI: A population-based natural experiment. Circulation 2007;115:2128-35.

Schneeweiss S, Setoguchi S, Weinblatt M, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti-TNFa therapy and the risk of serious bacterial infections. Arthritis Rheum 2007;56:1754-64. 

Schneeweiss S, Setoguchi S, Brookhart MA, Dormuth C, Wang PS. Mortality in users of Conventional and Atypical Antipsychotic Medications in British Columbia Senior. Can Med Assoc J 2007;176:627-32.

Setoguchi S, Avorn J, Glynn RJ, Mogun H, Schneeweiss S. Statin use and the risk of lung, breast, and colorectal cancer. Circulation 2007;115:27-33.

Schneeweiss S, Solomon DH, Wang PS, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective COX-2 inhibitors and non-selective NSAIDs: an instrumental variable analysis. Arthritis Rheum 2006;54:3390-8.

Setoguchi S, Solomon DH, Avorn J, Katz JN, Weinblatt ME, Glynn RJ, Cook EF, Carney G, Schneeweiss S. Use of anti-TNF alpha drugs and incidence of hematologic and solid cancers in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-64.

Schneeweiss S, Maclure M, Dormuth C, Glynn RJ, Canning C, Avorn J. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharm Ther 2006;79:379-88.

Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Safety 2006;15:291-303.

Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects in claims databases using physician-specific prescribing preferences as an instrumental variable. Epidemiology 2006;17:268-75.

Wang PS, Schneeweiss S, Avorn J, Fischer M, Mogun H, Solomon DH, Brookhart AM. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353;2335-41.

Sturmer T, Schneeweiss S, Avorn J, Glynn RJ: Correcting effect estimates for unmeasured confounding in cohort studies with validation studies using propensity score calibration. Am J Epidemiol 2005;162:279-89.

Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH: Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: The example of COX2 inhibitions and myocardial infarction. Epidemiology 2005;16:17-24.

Fischer MA, Schneeweiss S, Avorn J, Solomon DH: Impact of Medicaid prior authorization programs on use of COX-2 inhibitors. N Engl J Med 2004;351:2187-94.

Schneeweiss S, Wang P: Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. J Clin Psychopharm 2004;24:632-8.

Schneeweiss S, Dormuth C, Grootendorst P, Soumerai S, Maclure M: Net health plan savings from reference drug pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 2004;42:653-60.

Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J: The relationship between selective COX-2 inhibitors and acute myocardial infarction. Circulation 2004;109:2068-73.

Schneeweiss S, Maclure M, Carleton BC, Glynn RJ, Avorn J: Clinical and economic consequences of a formulary restriction of nebulized respiratory drugs in adults: Direct comparison of randomized and observational evaluations. Br Med J 2004;328:560-7.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ: Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharm Ther 2003;74:388-400.

Schneeweiss S, Wang PS, Avorn J, Glynn RJ: Improved Comorbidity Adjustment for Predicting Mortality in Medicare Populations. Health Services Research 2003;38:1103-20.

Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB: Outcomes of reference pricing for angiotensin-converting enzyme inhibitors. New Engl J Med 2002;346:822-9.

Schneeweiss S, Hasford J, Gottler M, Hoffmann A, Riethling A-K, Avorn J: Hospital admissions caused by adverse drug reactions: A longitudinal population-based study. Euro J Clin Pharm 2002;58: 285-91.

Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ: Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol 2002;55:833-41.

Schneeweiss S, Seeger J, Maclure M, Wang P, Avorn J, Glynn RJ: Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64.

Maclure M, Schneeweiss S: Causation of Bias: The Episcope. Epidemiology 2001;12:114-22.

Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29:891-8.

Schneeweiss S. Sensitivity analysis of the diagnostic value of endoscopies in cross-sectional studies in the absence of a gold standard. Int J Tech Ass Health Care 2000;16:834-41.

Schneeweiss S, Sturmer T, Maclure M: Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol and Drug Safety 1997;6 S3:51-9.

Spiegelman D, Schneeweiss S, McDermott A: Measurement error correction for logistic regression models with an “alloyed gold standard”. Am J Epidemiol 1997;145:184-96.